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Abstract
Purpose To retrospectively evaluate the age of onset of
MEN1-associated lesions in a group of affected children
and adolescents and to compare the clinical features of our
series with the evidence derived from the literature.
Methods The study population consisted of 22 Italian
children and adolescents (age 6–31 years at the time of the
inclusion in this study) all with a clinical and/or a genetic
diagnosis of MEN1 performed before the age of 16 who
have been followed-up regularly from 1998 to 2016 at the
Regional Referral Center for Hereditary Endocrine Tumors.
Clinical, biochemical, imaging and genetic data have been
collected for each patient.
Results Ten subjects (45.5%) have not yet presented any
clinical/biochemical/radiological manifestation of MEN1
disease, whereas 12 patients (54.5%) developed at least one
MEN1-associated endocrine manifestation. The second
group of patients was significantly older than the first one.
The most frequent manifestation was primary hyperpar-
athyroidism (50%), followed by pituitary tumors (prolacti-
nomas) (31.8%) and nonfunctioning pancreatic
neuroendocrine tumors (9%). The earliest cases of primary
hyperparathyroidism and prolactinoma were a 12-year-old
girl and a 13-year-old boy, respectively.
Conclusions MEN1 disease seems to present with different
features in children and adolescents from those in adults.
Our study confirms the fundamental importance of screen-
ing for tumors in young MEN1 patients beginning in early
childhood, in order to avoid diagnostic and therapeutic
delays.
Keywords Multiple endocrine neoplasia type 1 ● Clinical
diagnosis ● Genetic diagnosis ● Children and adolescents ●
Early onset ● Disease screening
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is a rare
autosomal dominant inherited multiple endocrine tumor
syndrome, mainly affecting parathyroid glands, gastro-
entero-pancreatic neuroendocrine tissues, and anterior
pituitary [1].
In children and adolescents, the MEN1 diagnosis is
principally made by the genetic screening of the MEN1
gene, within a pedigree with a previously identified MEN1
mutation.
Penetrance of MEN1 mutations is age-dependent; how-
ever, although it appears to be almost negligible before 5
years of age, clinical manifestations of MEN1 have occur-
red in some patients by the age of 5 years. Therefore,
Clinical Guidelines suggest the performance of genetic
testing in asymptomatic relatives of MEN1 mutated patients
as soon as possible, certainly within the first decade of life,
hopefully before 5 years of age [2].
Genetic testing presents numerous advantages: it requires
only a single blood sample, it can be performed at any age
and, in theory, it does not need to be repeated during life. A
negative genetic result allows us to avoid further MEN1
clinical surveillance in those subjects. It is fundamental to
regularly monitor all patients at high risk of developing
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MEN1-associated tumors (index cases and germline muta-
ted MEN1 carriers) using a specific screening program, in
order to promptly diagnose tumors throughout life without
any delay.
Screening should start during early childhood [3] and
continue throughout life, as the first clinical manifestations
can arise even during the eighth decade of life in some
patients [2]. Table 1 shows the age of initiation and mod-
alities of screening for each of the main MEN1-associated
tumors according to the latest MEN1 Guidelines; respective
levels of clinical evidence are also indicated [2].
The aim of our retrospective study is to evaluate the age
of onset of MEN1-associated lesions in a group of affected
Italian children and adolescents and to compare the clinical
features of our series with evidence on MEN1 in young
patients derived from literature.
Subjects and methods
The study population consists of 22 Italian children and
adolescents, aged from 6 to 31 years at the time of the
enrollment in the present study, all with a clinical and/or
genetic diagnosis of MEN1. All patients were regularly
followed-up at the Regional Referral Center for Hereditary
Endocrine Tumors of the Endocrine Unit in the Department
of Surgery and Translational Medicine, University Hospital
Careggi in Florence from 1998 to 2016. A total of 160
MEN1 patients (55 males and 105 females) were referred to
our Center and regularly evaluated during the same period
of time. The study was approved by the local ethics com-
mittee of Careggi Hospital, and informed consent has been
obtained from all legal guardians of our minor patients.
Patients were annually tested for parathyroid hormone
(PTH) and calcemia, prolactin (PRL), insulin-like growth
factor 1 (IGF-1), growth-hormone (GH), thyroid-
stimulating hormone (TSH), adrenocorticotropic hormone
(ACTH), gonadotropins, glycaemia, plasma insulin, C-
peptide, serum gastrin, plasma vasoactive intestinal peptide
(VIP), pancreatic polypeptide (PP), glucagon, and
chromogranin-A (CgA). Secretin provocative test was per-
formed every 12–18 months beginning at the age of 15.
Adrenal function was evaluated in case of clinical mani-
festations. Imaging tests were performed in the presence of
biochemical alterations and/or clinical signs and symptoms.
Particularly, abdominal computed tomography (CT)/mag-
netic resonance imaging (MRI) were performed every 2–3
years; if scintigraphy with somatostatin analogous was
positive in presence of gastro-entero-pancreatic neu-
roendocrine tumors (GEP-NETs), it was repeated every 2
years.
Clinical, biochemical, imaging and genetic data were
collected and recorded in a specific database in association
Table 1 Diagnostic screening of MEN1-associated tumors according to the latest MEN1 guidelines
Men1-associated disease Age of
initiation
(years)
Laboratory parameters Level of clinical
evidence
Imaging test Level of clinical
evidence
Primary hyperparathyroidism 8 Plasma calcium and PTH
(annually)
Strong
recommendation; high
quality
– –
Anterior pituitary tumors 5 Plasma PRL and IGF-1
(annually)
Weak recommendation;
moderate quality
MRI every 3 years Weak
recommendation;
low quality
Gastrinoma 20 Fasting serum gastrin
(annually) (±gastric pH;
diagnostic values < 2)
Weak recommendation;
low quality
– –
Insulinoma 5 Fasting plasma insulin and
glucose (annually)
Weak recommendation;
low quality
– –
Other pancreatic NET
(glucagonoma, VIPoma,
nonfunctioning pancreatic NET)
<10 Plasma glucagon, VIP, PP,
CgA (annually)
Weak recommendation;
low quality
CT, MRI or EUS
annually
Weak
recommendation;
low quality
*Bronchial and thymic carcinoid 15 None (no increase in plasma
CgA levels has been observed)
Strong
recommendation; high
quality
Chest CT or MRI
every 1–2 years
Weak
recommendation;
very low quality
Adrenal tumors <10 Only in case of suspected
clinical manifestations and/or if
the tumor size is >1 cm
Strong
recommendation;
moderate quality
Abdominal CT or
MRI annually with
pancreatic imaging
Weak
recommendation;
low quality
Notes: *screening should be performed even after prophylactic thymectomy
NET neuroendocrine tumor, PTH parathyroid hormone, PRL prolactin, IGF-1 insulin-like growth factor-1, VIP vasoactive intestinal peptide, PP
pancreatic polypeptide, CgA chromogranin-A, CT computed tomography, MRI magnetic resonance imaging, EUS endoscopic ultrasound, cm
centimeter
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with a specific, unique anonymous alphanumeric code to
assure the privacy of the patient, and each patient was
referred to in the study only by this identifying code. Data
collected in the database included: birth date, gender, age at
genetic diagnosis (date of genetic test), MEN1 gene muta-
tion, first MEN1 manifestation, age at clinical diagnosis
(date of the first clinical manifestation, defined as the
MEN1-associated lesion that was firstly discovered),
MEN1-associated endocrine manifestations, other comor-
bidities, MEN1-related surgical history and pharmacologi-
cal treatments.
Data included in the database are presented as percen-
tages, means and standard deviations and medians (range).
The comparison between the median age of MEN1
patients with and without at least one endocrine manifes-
tation of the disease was performed by Mann–Whitney U-
test. A p-value< 0.05 was considered as the level of sta-
tistical significance.
Twenty-one patients underwent the MEN1 genetic test
after a first degree relative was diagnosed with a MEN1
mutation; each was tested for the specific pedigree-
associated mutation by a PCR-based Sanger sequencing
of the specific mutation-containing exon or intron-exon
junction of the MEN1 gene. One patient was a proband; he
underwent MEN1 mutational analysis before all his family
members.
Results
Clinical, genetic, and therapeutic features of our series of
young MEN1 patients are summarized in Table 2.
A genetic and/or clinical diagnosis of MEN1 syndrome
was performed in all 22 subjects before the age of 16: 10
females (45.5%) and 12 males (54.5%). The cases were
familial, belonging to 14 different MEN1 pedigrees, and a
MEN1 mutation was identified in all cases. Only one patient
(case 4, Table 2) was a proband presenting the same age of
both genetic and clinical diagnosis, whose family has been
subsequently screened for MEN1 mutation. All other cases
were family members identified as MEN1 first via genetic
screening. The mean age at genetic diagnosis of MEN1 was
9.4± 3.75 years (range 0–14). The age at the genetic
diagnosis of the proband (case 4, Table 2) was 13 years,
whereas the age at MEN1 diagnosis of his brother and sister
was 7 and 10, respectively.
Genetic analysis confirmed the absence of mutational hot
spots in the MEN1 gene and mutations have been identified
all along MEN1 exons (except for exons 5, 6, and 7) and
intron-exon junctions (Table 2). In our series of patients, we
identified missense, nonsense, frameshift, and splicing site
mutations. Two brothers harbored a double mutation on the
same MEN1 allele, not associated with a higher aggres-
siveness of the syndrome (cases 11 and 12, Table 2).
To date, 10 subjects (45.5%) [median age 12 years
(range 6–16)] have not yet presented any clinical manifes-
tation associated with MEN1 and no abnormalities in bio-
chemical tests or evidence of the disease by imaging
examinations were detected (referred to as “still asympto-
matic” patients). Conversely, 12 patients (54.5%) [median
age 22.5 years (range 12–31)] developed at least one
MEN1-associated endocrine manifestation; in detail, 10 of
these patients were clinically asymptomatic and were
diagnosed by routine biochemical tests and/or imaging
investigations, whereas only two were symptomatic,
showing pituitary tumor-induced headache with visual dis-
turbances and primary hyperparathyroidism (PHPT)-related
kidney stones, respectively. A significant difference was
found in the median value of age between these two patient
groups (U-test= 5.0; p< 0.001). Particularly, patients with
MEN1-associated lesions were significantly older than
MEN1 patients without any clinical/biochemical/radi-
ological manifestation of the syndrome.
The most frequent clinical phenotype was PHPT which
was present in 11 patients (50%) [six females (54.5%) and
five males (45.5%)] followed by pituitary tumors (seven
cases; 31.8%) [four females (57.1%) and three males
(42.9%)] and pancreatic NETs (pNETs) (two females; 9%).
PHPT was the only manifestation of MEN1 in four cases,
while it was associated with other lesions in seven cases.
PHPT was the first MEN1 manifestation in 7 out of 12
patients (58.3%) who had developed MEN1-associated
clinical and/or biochemical and/or radiological abnormal-
ities; it was symptomatic (presence of a history of kidney
stones) in only one out of 11 patients with PHPT (9%).
Asymptomatic PHPT patients (10/11, 91%) were diagnosed
by biochemical tests. The earliest case of PHPT was an
asymptomatic normocalcemic 12-year-old girl. Patients
with low levels of vitamin D were treated with oral sup-
plements to exclude cases of secondary hyperparathyroid-
ism [4].
The patient with symptomatic PHPT underwent surgery
and then received pharmacological therapy; five asympto-
matic PHPT patients had normocalcemia that did not
require therapy and have been monitored with annual cal-
cemia and PTH measurements; the remaining five asymp-
tomatic patients were surgically and/or pharmacologically
treated because of hypercalcemia. Particularly, 2/5 patients
(40%) underwent total parathyroidectomy with autograft in
the non-dominant forearm, 1/5 (20%) subtotal para-
thyroidectomy, and 2/5 (40%) partial parathyroidectomy
(removal of only the single enlarged gland). Three out of
five patients who were surgically treated also underwent
total thymectomy. Pharmacological treatment of PHPT with
calcimimetics (cinacalcet) was performed as first line
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therapy in 2/11 patients (18%). To date, cinacalcet is the
current therapy in one patient (because she postponed sur-
gery for personal reasons); another patient underwent
parathyroidectomy after 3 years of pharmacological ther-
apy; another, who was the only symptomatic patient, was
treated with cinacalcet for persistent PHPT after para-
thyroidectomy. To date, all surgically and/or pharmacolo-
gically treated patients for PHPT show normocalcemia.
Pituitary tumors developed in seven patients [four
females (57%) and three males (43%)]. In one case (14.3%)
the pituitary tumor was the only manifestation of MEN1
disease, whereas it was associated with other lesions in six
patients (85.7%).
Pituitary tumors were the first manifestation in 4 out of
12 MEN1 patients who showed at least one MEN1-induced
clinical and/or laboratory and/or radiological alteration
(33.3%). All pituitary tumors were prolactinomas, and five
of them were clinically asymptomatic microadenomas. The
remaining two prolactinomas were macroadenomas; they
occurred in two young males (cases 4 and 17, Table 2). One
of these two patients, who was a proband and represented
the earliest case of prolactinoma in our series (13 years old),
complained of headache and visual disturbances and had a
macroprolactinoma-induced secondary hypogonadism,
which led to a severe osteoporosis requiring pharmacolo-
gical treatment with testosterone and neridronate (case 4,
Table 2). The other patient (case 17, Table 2) was clinically
asymptomatic. Prolactinomas were associated with a normal
remaining pituitary function in all patients except the pro-
band. Pharmacological approach with dopamine-agonists as
first-line therapy was performed in all patients. This is their
current therapy, which allows good control of the pituitary
disease in all patients to date, except for those with mac-
roprolactinoma who show hyperprolactinemia (case 4 and
17, Table 2).
Two females developed nonfunctioning pNETs, both
revealed by CT. Both pNETs were associated with other
MEN1-related lesions. One patient had two non-secreting
lesions of 0.6 and 0.7 centimeters (cm) in size at the pan-
creatic head/body and body/tail crosses, respectively (case
7, Table 2); the other patient had a 1.3 cm lesion in the
pancreatic tail, which secreted glucagon and scintigraphy
with somatostatin analogous was positive, so pharmacolo-
gical therapy with somatostatin analogous was performed as
first-line therapy (case 5, Table 2). To date, neither pNET
has been removed because they are stable in size at annual
imaging follow-up. No cases of insulinoma, gastrinoma or
other GEP-NETs occurred in our small series of MEN1
patients. Patients who underwent secretin provocative test
showed a normal response.
Lipomas were present in two patients and, notably, this
was the first clinical sign of MEN1 disease in one patient
(case 6, Table 2).
To date, no other MEN1-associated lesions have mani-
fested in our patients, particularly no cases of adrenal
lesions or thymic NET have emerged.
Notably, neonatal hypocalcaemia occurred in one patient
(case 18, Table 2), because his mother had hyperparathyr-
oidism during pregnancy (MEN1 not yet diagnosed in the
mother).
Discussion
MEN1 is a rare disease and the penetrance of MEN1
mutations is known to be progressive during life [3]. This is
confirmed in our study, which shows that patients with at
least one manifestation of MEN1 syndrome are significantly
older than those without any clinical/biochemical/radi-
ological expression of the disease. Hence, large clinical
studies in children with MEN1 are lacking and most of the
current knowledge is related to MEN1 in adults.
Evidence of MEN1 in childhood mainly derives from
case reports, but a retrospective study performed in a large
group of 160 MEN1 patients (96 females and 64 males)
under 21 years of age has recently been published by
Goudet et al. [3]. At the time of the study, the age of 21 had
been reached by 67% of patients, the age of 15 by 90%, the
age of 10 by 97%, and the age of 5 by all patients. The
study showed that the frequency of MEN1-associated
tumors in children was quite different than adults: PHPT
was the most frequent clinical manifestation also in children
(75%), whereas, contrary to adults, pituitary adenomas were
the second in frequency (34%), followed by GEP-NET
(23%). These results are confirmed in our series, and they
may be partly explained by different diagnostic approaches
between young and adult MEN1 patients. Particularly,
regular screening of MEN1 patients beginning in childhood
allows prompt diagnosis of still asymptomatic tumors,
whereas MEN1 diagnosis in adults might more often derive
from tumor-associated clinical symptomatology.
Our study also showed that PHPT was the most frequent
manifestation of onset in young MEN1 patients (58.3%),
whereas prolactinoma was the second most frequent mani-
festation of MEN1 onset (33.3%). Similarly, Goudet et al.
[3] showed that PHPT was the first laboratory and/or clin-
ical manifestation of the syndrome in 56% of patients, while
MEN1 onset was revealed by a pituitary adenoma in 21% of
cases.
In agreement with Goudet et al. [3], PHPT was mainly
asymptomatic in our series of MEN1 patients (10/11
patients; 91%), and only one young girl presented with
symptomatic urolithiasis. All cases of PHPT occurred after
10 years of age in our study group, and this was partly in
agreement with the study of Goudet et al. [3], in which 90%
of PHPT cases occurred after 10 years, but the earliest
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asymptomatic and symptomatic cases were a 4-year-old boy
and an 8-year-old girl, respectively [3].
One single case of a severe complication of MEN1-
associated PHPT is reported in literature: a MEN1 boy
experiencing a PHPT-related ischemic stroke, in absence of
hypertension, at the age of 14 [5].
Thirteen clinical cases (cases 1 to 13) of children and
adolescents with MEN1-related pituitary disease derived
from literature are summarized in Table 3.
MEN1-associated pituitary adenomas are known to be
more frequent in females [2], with a 3.2/1 female/male ratio
during the pediatric age, although macroadenomas appear to
be more frequent in young males than in young females [3],
and a greater aggressiveness of pituitary tumors in young
males rather than in young females seems to arise from
current evidence [3, 6–9] (cases 1–4, Table 3). Results from
our series appear to confirm this aspect, as patients with
PRL-secreting macroadenoma were all young males (case 4
and 17, Table 2).
Nevertheless, literature also reported the case of a 6.5-
year-old girl with an invasive suprasellar pituitary macro-
adenoma [10] (case 5, Table 3).
In agreement with Goudet et al. [3], no pituitary tumor
occurred before the age of 10 in our series of patients,
although it could not be excluded that the real age of onset
of the macroprolactinoma in our proband, which was
diagnosed at age 13, was earlier. MEN1 Guidelines suggest
an earlier beginning of the screening, at the age of 5 years
[2] (Table 1). Some case reports of MEN1 children who
developed pituitary tumors much earlier than the age of 10
are described and all three young patients had functioning
macroadenomas with features of aggressiveness and treat-
ment-resistance, thus suggesting a possible association
between early development during childhood and aggres-
sive biological behavior of pituitary tumors (cases 1, 2, and
5, Table 3) [6, 7, 10]. Diagnostic delay seems to be quite
common, ranging from almost 1.5 years to 4 years [3, 6–8,
11] (cases 1–3, 6–8, Table 3), and it can severely com-
promise patients, particularly when pituitary tumors have an
aggressive biological behavior.
According to current evidence [3], our series appears to
show that prolactinomas were the most frequent MEN1-
associated pituitary tumors in childhood, similar to
adulthood.
Despite the absence of young MEN1 patients with
pituitary-related chronic hypercortisolism in our series and
the small number of these cases reported by Goudet et al.
[3], at least six cases of children with MEN1-associated
Cushing’s disease have been described in literature [9, 11]
(cases 4,6–8,9,10, Table 3).
Two cases of regularly screened MEN1 girls with
pituitary tumors among the other manifestations of the
syndrome are reported in Table 3 (cases 12 and 13) [12].
Although MEN1 syndrome was known not to be asso-
ciated with a higher incidence of pituitary carcinoma [2],
and no cases occurred in our series nor in the study of
Goudet et al. [3], the case of a MEN1 boy who developed a
TSH-secreting pituitary carcinoma at age 19 was reported in
literature [13] (case 11, Table 3).
The crucial role of patient monitoring emerges from our
series, as most patients with prolactinoma were clinically
asymptomatic, because the screening allowed an early
laboratory and/or radiological diagnosis prior to the devel-
opment of clinical manifestations, granting early therapeutic
intervention. Moreover, the occurrence of a pituitary ade-
noma during childhood and adolescence should lead clin-
icians suspect MEN1 disease. Indeed, a broad study
analyzing 174 not-hypercalcemic patients with a sporadic
pituitary macroadenoma showed that 3 out of 46 pediatric
patients (≤18 years) suffered from MEN1, thus revealing
that such adenomas were just “apparently” sporadic [14].
Considering the clinical triad of MEN1 [2], our limited
series of children and adolescents showed that GEP-NETs
were the rarest lesion in young MEN1 patients, in accor-
dance with Goudet et al. [3]. To date, our patients devel-
oped only nonfunctioning pNETs, and no cases of other
types of GEP-NET occurred in our study group, particularly
no cases of insulinoma or gastrinoma have manifested.
Conversely, Goudet et al. [3] showed that insulinomas
were the most frequent GEP-NET (12%), followed by
nonfunctioning pNET (9%), and gastrinomas (2%) [3]. Data
of Gonçalves et al. [15] seemed to confirm our evidence on
nonfunctioning pNETs, showing a higher penetrance of
nonfunctioning pNETs (42%) than insulinomas (11%) in
MEN1 patients from age 12 to 20. The higher frequency of
nonfunctioning pNET reported by Gonçalves et al. [15]
with respect to Goudet et al. could be partly due to the
systematic use of endoscopic ultrasound (EUS) to monitor
young MEN1 patients, as EUS is more sensitive than MRI
or CT and can reveal pancreatic tumors <1 cm in size in
asymptomatic patients.
Based on the available literature, MEN1-associated
insulinoma appears to have two main features: the pre-
cocity of its onset and its significant diagnostic delay both in
the pediatric population [3] and in adulthood [16]. Symp-
toms of neuroglycopenia could be attributed to less rare
diseases, such as epilepsy, and this could partly explain the
diagnostic delay. Therefore, it is very important to start
screening MEN1 patients for insulinoma beginning at the
age of 5 [2, 3], and to educate the parents of MEN1 children
to recognize clinical manifestations of insulinoma [3].
Table 3 shows two cases of children with insulinoma as
the first clinical manifestation of MEN 1 [17, 18] (cases 14
and 15).
Nonfunctioning pNETs can usually be revealed through
radiological investigation, because they are not hormone-
Endocrine
Table 3 Clinical cases of pituitary disease and pancreatic NET in MEN1 children and adolescents
Case
number
Gender Index
case
First clinical
manifestation(s) of
MEN1
Age at
diagnosis of the
first clinical
manifestation(s)
of MEN1
(years)
Age at first clinical
suspicion (years)
Other MEN1-
associated lesions
Genetic information Treatments Reference
number
1 M Yes Acceleration of growth
and IGF1 excess-related
facial features in
presence of an invasive
GH/PRL-secreting
pituitary macroadenoma
inducing optic chiasm
compression
5 3.5= acceleration of
growth
(+13 cm/year), and
weight gain
Nothing Familial MEN1
(His139Asp; exon 2)
Bromocriptine (ineffective); L-
thyroxin for secondary
hypothyroidism. Subsequently,
transsphenoidaladenomectomy
(not curative). Pergolide, then
substituted by cabergoline
(partial control of the disease)
+octreotide (normalization of
IGF1 levels)
6
– – – – 4=worsening
headache
– – –
2 M Yes Visual disturbance
caused by a giant
prolactinoma with
suprasellar extension
inducing optic chiasm
compression, severe
hyperprolactinemia, and
partial hypopituitarism
(TSH and GH)
11 7= chronic headache Subsequent primary
hyperparathyroidism
Familial MEN1
(consanguinity)
(intronic mutation
784–9 G>A
determining the
synthesis of a
truncated inactive
protein)
L-thyroxin; cabergoline with
late treatment-resistance and
dual recurrence of pituitary
disease, both times treated with
surgical debulking (+RT after
the 2° one) complicated by
panhypopituitarism. Planned
parathyroidectomy
7
– – – – 9.5= progressive
visual impairment
– – – –
3 M Yes Visual disturbance,
headache, mild nausea,
height gain (+5 cm),
and feet enlargement
due to PRL/partially
GH-secreting pituitary
macroadenoma with
suprasellar extension
inducing obstructive
hydrocephalus,
bitemporalhemianopsia,
and secondary
hypogonadism
19 15= induced
galactorrhea
Simultaneous
diagnosis of primary
hyperparathyroidism
and a partially cystic
pancreatic tumor
associated with
increased levels of
plasma insulin
Familial MEN1
(monosomy of
chromosome 11 in
pituitary adenoma)
Cabergoline (treatment-
resistance), therefore
transsphenoidal pituitary
surgery
8
– – – – 18.5= begin of overt
clinical
symptomatology
– – – –
4 M Not
reported
*Cushing’s syndrome
due to an invasive
pituitary microadenoma
positive for ACTH
(simultaneous presence
of a pituitary
macroadenoma positive
for PRL)
*10 Not reported Angiofibromas Familial MEN1 Pituitary surgery (clinically
curative)
9
5 F Not
reported
*Visual disturbance and
acceleration of growth
due to an invasive GH-
secreting pituitary
macroadenoma with
suprasellarand lateral
extension inducing optic
chiasm compression
*6.5 Not reported Not reported Familial history of
pituitary adenomas
(c.765–6 C→T-
splicing site; intron
3)
Transsphenoidal surgery;
octreotide; subsequent
pituitary surgery three
additional times, then
cabergoline, then RT with final
persistence of biochemically
active disease and radiological
evidence of the adenoma,
although reduced in size
10
6 M,
twin
Yes Cushing’s disease due to
pituitary microadenoma
13 9= deceleration of
growth
Primary
hyperparathyroìdism
with urolithiasis
Familial MEN1
(Tyr351His; exon 8)
Transsphenoidaladeno-
mectomy at the time of the
diagnosis
11
7 F Yes Cushing’s disease due to
pituitary microadenoma
11.5 7.5–8.5=
deceleration of linear
growth and weight
gain
Asymptomatic
primary
hyperparathy-
roidism; lipoma of
the shoulder
Familial MEN1
(Tyr351His; exon 8)
Transsphenoidaladeno-
mectomy at the time of the
diagnosis. Surgical removal of
the lipoma at the age of 16
11
8 F Yes Cushing’s disease due to
pituitary microadenoma
12.5 9= progressive
obesity and
deceleration of
growth
Primary
hyperparathyroidism
Non-familial MEN1
(Leu444Pro; codon
44 exon 9)
Transsphenoidaladeno-
mectomy at the time of the
diagnosis
11
9 M Not
reported
*Cushing’s syndrome in
presence of 2 pituitary
microadenomas both
positive for PRL and
negative for ACTH plus
a left adrenal lesion<1
cm in size
*15 Not reported Primary
hyperparathyroidism
Familial MEN1 Pituitary surgery (clinically
curative)
9
10 M Not
reported
*Cushing’s syndrome
with normal hypophysis
also at the surgical
exploration; adrenal
imaging not determined
*14 Not reported Primary
hyperparathyroidism
Familial MEN1 Blind left
hemihypophysectomy
(clinically curative)
9
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producing, or they secrete insufficient amounts of hor-
mones, such as PP or glucagon, to induce clinical signs and
symptoms [2]. Consequently, as patients are asymptomatic,
imaging screening is fundamental for a timely diagnosis.
Literature highlights the high frequency of non-
functioning pNETs in young patients with MEN1 [15], the
uncertainty of their biological behavior, and the need for a
careful radiological monitoring of young MEN1 patients
[12]. Two clinical cases of young girls with asymptomatic
nonfunctioning pNETs with uncertain malignant potential
were described by Newey et al. [12] (cases 12 and 13,
Table 3).
Based on results from our study, we also recommend
careful and regular monitoring of young MEN1 patients
for nonfunctioning pNETs through radiological imaging
and test for specific pancreatic hormones, such as glucagon
and PP.
Little data on MEN1-associated gastrinomas in child-
hood is available because they are rare in children, as
opposed to in adults [3].
Given the aggressive natural history of MEN1-associated
gastrinoma during childhood, and the precocious age of
onset [3], despite its rarity in pediatric MEN1 patients [2, 3],
Goudet et al. proposed an early initiation of annual serum
gastrin screening at the age of 10 [3]. However, normal
levels of gastrin do not allow us to exclude the diagnosis of
gastrinoma [3], and, therefore, secretin provocative tests
might be helpful. Moreover, the restoration of normo-
calcemia after the treatment of PHPT in MEN1 patients
with gastrinoma could normalize the level of fasting serum
gastrin and the response to the secretin provocative test
despite the presence of the gastrinoma itself, whereas the
influence of the correction of PHPT-related hypercalcemia
on the growth of MEN1-associated gastrinoma is not known
Table 3 continued
Case
number
Gender Index
case
First clinical
manifestation(s) of
MEN1
Age at
diagnosis of the
first clinical
manifestation(s)
of MEN1
(years)
Age at first clinical
suspicion (years)
Other MEN1-
associated lesions
Genetic information Treatments Reference
number
11 M Not
reported
*Visual disturbance due
to TSH-secreting
pituitary carcinoma
*19 Not reported Primary hyperpara-
thyroidism;
pancreatic islet cell
tumors associated
with liver
adenomegaly;
(slowly-growing
periprostatic mass)
Not reported Transfrontalhypophysectomy
+ RT; pituitary hormone
replacement therapy. At the
age of 28, occurrence of TSH-
secreting carcinoma metastasis
at foramen magnum, vertebral
bodies, and intradural spinal
level, which were surgically
treated (+PTU); octreotide
chronically. Total
parathyroidectomy
13
12 F no
(screened
patient)
Nonfunctioning NET
with uncertain
malignant potential of
the neck of the
pancreas;
oligomenorrhea due to
hyperprolactinemia
associated with pituitary
adenoma; asymptomatic
primary
hyperparathyroidism
14 – – Familial MEN1
(frameshift)
Partial pancreatectomy after an
initial period of surveillance;
cabergoline
12
13 F no
(screened
patient
since the
age of 7)
Nonfunctioning NET
with uncertain
malignant potential of
the distal segment of the
pancreatic body;
nonfunctioning pituitary
microadenoma
12 – – Familial MEN1
(Gln349Stop)
Distal pancreatectomywith
splenectomy
12
14 M Yes Seizures, hypoglycemic
symptoms, and weight
gain (8 Kg during
4 months) due to
insulinoma (two
pancreatic lesions)
8 8 Primary
hyperparathyroidism
at the age of 16;
hyperprolactinemia
with negative MRI
at the age of 25
Familial MEN1
(IVS4–9G>A;
intron 4)
Partial pancreatectomy;
subtotal parathyroidectomy
17
15 F Yes Sudden loss of balance,
tremors, and 5 min-long
tonic-clonic seizures
due to an insulinoma of
the head of the pancreas
9 8= begin of the
weight gain (+10 Kg
between 8 and 9
years old)
Nothing after 1 year
of follow-up
Familial MEN1
(Asn374Argfs*3;
exon 8)
Enucleation of the pancreatic
mass
18
Notes: *it is not known whether the reported clinical manifestations (and the corresponding age of their diagnosis) truly represent the first clinical
manifestation of onset of MEN1 syndrome
M male, F female, IGF-1 insulin-like growth factor-1, GH growth hormone, PRL prolactin, TSH thyroid-stimulating hormone, ACTH
adrenocorticotrophic hormone, NET neuroendocrine tumor, PTU propylthiouracil, RT radiotherapy, MRI magnetic resonance imaging, cm
centimeters, Kg kilograms
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[19]. The importance of educating the parents of MEN1
children in the recognition of Zollinger-Ellison syndrome
through its symptomatology is crucial [3].
To date, adrenal lesions have not manifested in our
patients and very few data are currently available on adrenal
lesions in MEN1 children and adolescents.
Pituitary-associated Cushing’s disease appears to be
more frequent than Cushing’s syndrome caused by adrenal
lesions in pediatric MEN1 patients [3, 9, 11].
The possibility of androgen hypersecretion in young
MEN1 patients with an adrenal lesion should be kept in
mind, which could reveal the presence of an adrenal car-
cinoma, a rare tumor that can be highly aggressive [3].
Another MEN1-associated tumor which is very rare, but
extremely aggressive, is thymic NET [2, 3]. No cases of
such a rare tumor occurred in our series, but both young
MEN1 patients with a thymic NET described in the litera-
ture died early from metastatic disease [3, 20].
MEN1 Guidelines suggest regular monitoring for this
tumor even after prophylactic thymectomy [2].
In conclusion, MEN1 seems to have partially different
manifestations in children and adolescents than in adults,
and this may be partly justified by different diagnostic
approaches between the two groups. Despite the paucity of
data in literature, current evidence highlights the funda-
mental importance of screening for tumors in young patients
with MEN1 beginning in early childhood, because clinical
manifestations can occur very early, even before age 5, but
we do not have sufficient experience regarding very early
onset of MEN1 disease. We also strongly recommend
regular monitoring of young patients at high risk of devel-
oping MEN1-associated lesions beginning in early child-
hood. Clinicians must be continuously attentive to the
earliest signs and symptoms of MEN1-associated tumors in
order to avoid diagnostic delays that could seriously jeo-
pardize the health and survival of young patients.
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